Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
Open Access
- 1 May 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5), 1310
- https://doi.org/10.3390/jcm9051310
Abstract
In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic musculoskeletal disorders (RMDs). The charts of RMD patients treated with the first-line bDMARD were reviewed, collecting data on safety, efficacy and comorbidities at prescription (baseline, BL), after 6 months (6M) and at last observation on bDMARD (last observation time, LoT). In 383 RMD patients, a higher rate of adverse events at 6M (p = 0.0402) and at LoT (p = 0.0462) was present in dyslipidemic patients. Patients who developed dyslipidemia or SAH during bDMARD treatment had similar results (dyslipidemia p = 0.0007; SAH p = 0.0319) with a longer bDMARD retention as well (dyslipidemia p < 0.0001; SAH p < 0.0001). SAH patients on angiotensin converting enzyme inhibitors (ACEis) or angiotensin-II receptor blockers (ARBs) continued bDMARDs for longer than non-exposed patients (p = 0.001), with higher frequency of drug interruption for long-standing remission rather than inefficacy or adverse reactions (p = 0.0258). Similarly, dyslipidemic patients on statins had a better bDMARD retention than not-exposed patients (p = 0.0420). In conclusion, SAH and dyslipidemia may be associated with higher frequency of adverse events but a better drug retention of first-line bDMARD in RMDs, suggesting an additional effect of ACEis/ARBs or statins on the inflammatory process and supporting their use in RMD bDMARD patients with SAH/dyslipidemia.This publication has 18 references indexed in Scilit:
- Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta‐AnalysisArthritis & Rheumatology, 2014
- Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patientsJournal of Human Hypertension, 2013
- Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent‐Onset Rheumatoid Arthritis PatientsArthritis Care & Research, 2013
- Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicineArthritis Care & Research, 2012
- Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysisAnnals Of The Rheumatic Diseases, 2012
- Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2006
- Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory ActionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trialThe Lancet, 2004
- Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-κB, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory ActionJournal of Clinical Endocrinology & Metabolism, 2003
- CAPTOPRIL: A NEW TREATMENT FOR RHEUMATOID ARTHRITIS?The Lancet, 1984